These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2611010)

  • 1. [Pharmacy in the 90's: the modern process of drug registration].
    Pasotti V
    Boll Chim Farm; 1989; 128(7-8):248-52. PubMed ID: 2611010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
    Smart A; Martin P
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Packaging of pharmaceuticals: still too many dangers but several encouraging initiatives.
    Prescrire Int; 2007 Jun; 16(89):126-8. PubMed ID: 17585428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When medicine becomes a disease.
    Arabia; 1986 Mar; 5(55):32-6. PubMed ID: 12340711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Drug Development: New Targets for Cancer Treatment.
    Curt GA
    Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma.
    Eichler HG; Pignatti F; Flamion B; Leufkens H; Breckenridge A
    Nat Rev Drug Discov; 2008 Oct; 7(10):818-26. PubMed ID: 18787530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marketing authorization of veterinary medicinal products in Poland.
    Sztabińska-Koncka H; Lewicki J
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):129-33. PubMed ID: 9339489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
    Ekimoto H
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Crisis and evolution in the field of pharmacy?].
    Mariani L
    Clin Ter; 1997 Apr; 148(4):129-32. PubMed ID: 9377847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Objectives and organization of the International Conference on Harmonization].
    Juillet Y
    Ann Pharm Fr; 1999 Mar; 57(2):137-42. PubMed ID: 10365469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical process research and development in the 21st century: challenges, strategies, and solutions from a pharmaceutical industry perspective.
    Federsel HJ
    Acc Chem Res; 2009 May; 42(5):671-80. PubMed ID: 19338294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Exclusivity of data in drug registration files and Israel's international status with regard to intellectual property rights protection].
    Lipschitz Y; Tamir O; Shemer J
    Harefuah; 2004 Dec; 143(12):845-8, 912. PubMed ID: 15666700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.